These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37803074)

  • 1. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
    Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
    Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
    Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
    BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
    Wang R; Yamada T; Arai S; Fukuda K; Taniguchi H; Tanimoto A; Nishiyama A; Takeuchi S; Yamashita K; Ohtsubo K; Matsui J; Onoda N; Hirata E; Taira S; Yano S
    Mol Cancer Ther; 2019 May; 18(5):947-956. PubMed ID: 30926637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
    Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
    Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
    Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
    Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
    Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
    Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
    Kim SM; Park K; Lim JH; Yun HJ; Kim SY; Choi KH; Kim CW; Lee JH; Weicker R; Pan CH; Park KC
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
    Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
    Wang HL; Ma X; Guan XY; Song C; Li GB; Yu YM; Yang LL
    Pharmacol Res; 2022 Mar; 177():106050. PubMed ID: 34973468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
    Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Anticancer Activity of
    Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.